New hope for kidney transplant patients: trial combines drugs to fight rejection
NCT ID NCT07006532
First seen Feb 19, 2026 · Last updated Jun 14, 2026 · Updated 17 times
Summary
This study tests whether adding a drug called tocilizumab to the usual treatment (IVIG, plasmapheresis, and rituximab) can better control chronic active antibody-mediated rejection (CAMR) in kidney transplant recipients. CAMR is a serious condition that often leads to kidney loss, and current treatments have limited success. The trial will enroll 50 adults with stable kidney function and certain biopsy findings, comparing the two treatment approaches over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY TRANSPLANT REJECTION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Nooshin Dalili
RECRUITINGTehran, 1666663421, Iran
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.